Cantor Fitzgerald starts AbbVie with an Overweight rating and $210 target, citing strong drug growth, low risk, and no major ...

AbbVie ( NYSE: ABBV) is set to report its first-quarter 2025 earnings on Friday, April 25, ahead of the market open. Wall ...

Investors will likely focus on the sales performance of AbbVie's blockbuster immunology drugs, Rinvoq and Skyrizi, when it ...

AbbVie bounced back after strong fourth-quarter results, but tariff fears and market volatility have sent shares tumbling ...

Discover AbbVie's strong performance, with immunology growth and undervaluation despite challenges. Click here to read an analysis of ABBV stock now.

Additionally, AbbVie developed new immunology drugs in Skyrizi and Rinvoq.These moves are paying off. Skyrizi and Rinvoq were two of AbbVie's top three sellers in 2024. AbbVie's revenue dropped ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

Last year, AbbVie’s Skyrizi and Rinvoq were practically unshakeable atop the monthly TV drug ad spending rankings, ultimately leading the pair of immunology meds to take the full-year title for ...

Passive income is essential in retirement, but building a dependable stream isn't easy. Fortunately, top-tier dividend stocks ...

We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a ...